"May we be the bridge and boat to cross the water": Community-engaged research on metta meditation.

Inclusive research is needed to understand how contemplative practices are used by people of diverse identities. Metta meditation-also known as loving-kindness meditation-may be particularly relevant for people committed to equity and justice because of the social nature of the practice. Using community-based participatory research and an intersectional framework, we assessed how people in a diverse meditation community teach and practice metta meditation.

Emergency medical services level of training is associated with mortality in trauma patients: A combined prehospital and in hospital database analysis.

Background: There is conflicting evidence regarding emergency medical service (EMS) provider level of training and outcomes in trauma. We hypothesized that advanced life support (ALS) provider transport is associated with lower mortality compared with basic life support transport.

Methods: We performed secondary analysis of a combined prehospital and in-hospital database of trauma patients utilizing ESO electronic medical records from 2018 to 2022.

Biomarkers.

Background: Alzheimer's disease is a devastating neurodegenerative disorder with a complex pathogenesis. One main pathological feature utilised in diagnosis is neurodegeneration or neuronal injury, which is reflected in reductions in cerebral glucose metabolism measured by [18F]Fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET). Here we evaluated the involvement of glial reactivity measured with magnetic resonance spectroscopy (MRS) and cerebral blood flow measured with arterial spin labelling (ASL) on [18F]FDG PET as a measure of cerebral glucose metabolism.

Public Health.

Background: Recent therapeutic successes in the treatment of Alzheimer's disease (AD), and diagnostic tools such as blood-based biomarkers, have energised the field to develop more specific diagnostics and therapies following the best principles of precision medicine. Large, 'real-world' cohorts are needed to understand whether these, and other future breakthroughs, are valid when employed in the wider AD community.

Methods: Our cohort study will provide a well-phenotyped (combining data on risk factors for neurodegenerative disease, cognitive assessment results, disease biomarkers and genetics) population aged 50 and above across the spectrum of risk for, and the earliest disease stages of, neurodegeneration (beginning in Scotland).

Drug Development.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.